Leflunomide-Sulfasalazine-Hydroxychloroquine — Competitive Intelligence Brief

Leflunomide-Sulfasalazine-Hydroxychloroquine (Leflunomide-Sulfasalazine-Hydroxychloroquine) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Disease-modifying antirheumatic drug (DMARD) combination. Area: Immunology / Rheumatology.

phase 3 Disease-modifying antirheumatic drug (DMARD) combination Multiple targets: dihydroorotate dehydrogenase (leflunomide), NF-κB pathway (sulfasalazine), lysosomal function and TLR signaling (hydroxychloroquine) Immunology / Rheumatology Small molecule

Target snapshot

Leflunomide-Sulfasalazine-Hydroxychloroquine (Leflunomide-Sulfasalazine-Hydroxychloroquine) — University of Nebraska. This triple-drug combination suppresses immune system activity through multiple pathways to reduce inflammation and autoimmune disease progression.

Comparator set (5 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Leflunomide-Sulfasalazine-Hydroxychloroquine TARGET	Leflunomide-Sulfasalazine-Hydroxychloroquine	University of Nebraska	phase 3	Disease-modifying antirheumatic drug (DMARD) combination	Multiple targets: dihydroorotate dehydrogenase (leflunomide), NF-κB pathway (sulfasalazine), lysosomal function and TLR signaling (hydroxychloroquine)
Methotrexate plus sulfasalazine	Methotrexate plus sulfasalazine	Singapore General Hospital	marketed	Disease-modifying antirheumatic drug (DMARD) combination	Multiple (dihydrofolate reductase, folate metabolism; sulfapyridine and 5-ASA mechanisms)
Leflunomide plus Methotrexate	Leflunomide plus Methotrexate	Bangladesh Medical University	marketed	Disease-modifying antirheumatic drug (DMARD) combination	Dihydroorotate dehydrogenase (leflunomide); Dihydrofolate reductase (methotrexate)
Methotrexate-Sulfasalazine-Hydroxychloroquine	Methotrexate-Sulfasalazine-Hydroxychloroquine	University of Nebraska	phase 3	Disease-modifying antirheumatic drug (DMARD) combination
Combination of DMARDs	Combination of DMARDs	Helsinki University Central Hospital	phase 3	Disease-modifying antirheumatic drug (DMARD) combination
Methotrexate, Hydroxychloroquine	Methotrexate, Hydroxychloroquine	Sanjay Gandhi Postgraduate Institute of Medical Sciences	phase 3	Immunosuppressive/Disease-modifying antirheumatic drug (DMARD) combination	Dihydrofolate reductase (methotrexate); Toll-like receptors and lysosomal pH (hydroxychloroquine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Disease-modifying antirheumatic drug (DMARD) combination class)

1. University of Nebraska · 2 drugs in this class
2. Bangladesh Medical University · 1 drug in this class
3. Helsinki University Central Hospital · 1 drug in this class
4. Singapore General Hospital · 1 drug in this class